Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older
Study Overview
The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older.
- Treatment
-
- RSV/hMPV mRNA / LNP 1 at 3-4 different doses or,
- RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or,
- RSV mRNA / LNP 1 at 1 dose or,
- hMPV mRNA / LNP 1 at 1 dose
Study details
Study duration per participant is approximately 6 months.
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Respiratory Syncytial Virus Infection, Healthy Volunteers, Metapneumovirus Infection
-
Age: 18 Years
-
Gender: All
Inclusion Criteria:
-Informed consent form (ICF) has been signed and dated
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
-Any condition which, in the opinion of the Investigator, might interfere with the
evaluation of the study objectives.
--The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Find a Study Location to Connect
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
